Efficacy of Low-dose (10 mg) Rosuvastatin in Korean 4 Statin Benefit Groups Per 2013 ACC/AHA Guideline
AssessmeNt of Efficacy of Low-dose rosuvaStatin in KoRean 4 Statin Benefit Groups Per 2013 ACC/AHA Guideline
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- subjects with prior history of clinical ASCVD
- subjects with primary elevation of LDL cholesterol ≥190 mg/dL
- subjects with diabetes, age 40 to 75 years, and LDL cholesterol 70 to 189 mg/dL
- subjects without diabetes, age 40 to 75 years, LDL cholesterol 70 to 189 mg/dL, and with estimated 10-year ASCVD risk ≥7.5%.
Exclusion Criteria:
- history of significant statin-induced rhabdomyolysis or myopathy
- history of a significant hypersensitivity reaction to rosuvastatin
- uncontrolled diabetes mellitus (HbA1c >9%)
- uncontrolled hypertension (systolic blood pressure >190 mmHg or diastolic blood pressure >100 mmHg)
- current active liver disease (alanine aminotransferase and/or aspartate aminotransferase >2 times the upper limit of normal)
- chronic kidney disease (serum creatinine clearance <30 ml/min)
- creatine kinase levels >3 times the upper limit of normal
- use of prohibited concomitant therapies
- history of malignancy within the last 5 years
- women who were pregnant, breast-feeding or of childbearing potential without contraception
- subjects who would take any medication for purposes other than this trial within 30 days after taking this study's medication.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Low-dose (10mg) rosuvastatin
Four statin benefit groups per 2013 ACC/AHA guideline in Korea
|
Low-dose (10mg) rosuvastatin in 4 statin benefit groups per 2013 ACC/AHA guideline
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage reduction in low-density lipoprotein (LDL) cholesterol
Time Frame: 8 weeks
|
Percentage reduction in low-density lipoprotein (LDL) cholesterol from baseline to 8 weeks of treatment
|
8 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage reduction in other lipids
Time Frame: 8 weeks
|
Percent changes from baseline to 8 weeks in total cholesterol, high-density lipoprotein (HDL) cholesterol, triglyceride (TG), non-HDL cholesterol, apolipoprotein B, apolipoprotein A1
|
8 weeks
|
|
Achievement of ≥50% reduction in LDL cholesterol
Time Frame: 8 weeks
|
Achievement of ≥50% reduction in LDL cholesterol with use of rosuvastatin 10 mg in 8 weeks
|
8 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Hyo-Soo Kim, MD., PhD., Seoul National University Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Metabolic Diseases
- Lipid Metabolism Disorders
- Nutritional and Metabolic Diseases
- Dyslipidemias
- Sulfur Compounds
- Organic Chemicals
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Hydrocarbons
- Amides
- Pyrimidines
- Hydrocarbons, Halogenated
- Sulfonamides
- Sulfones
- Fluorobenzenes
- Hydrocarbons, Fluorinated
- Rosuvastatin Calcium
Other Study ID Numbers
Other Study ID Numbers
- NewStaR4G
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.